Semaglutide Side Effects: Safety Signals and Warnings
Semaglutide safety concerns are compound-specific. The main listed side effects are Nausea (most common, usually transient), Vomiting, and Diarrhea. The main warning signals are Boxed warning: thyroid C-cell tumors in rodents, Contraindicated with personal/family history of medullary thyroid carcinoma, and Risk of pancreatitis.
Direct Answer
Semaglutide remains the best-validated GLP-1-only agent: FDA-approved for diabetes, obesity, cardiovascular risk reduction, and now higher-dose Wegovy HD 7.2mg. Tirzepatide beats it on weight loss in direct obesity trials, but semaglutide still has the deepest cardiovascular outcomes record and the broadest GLP-1 evidence base.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- Obesity, type 2 diabetes, cardiovascular risk reduction in overweight patients
Reported Side Effects
- Nausea (most common, usually transient)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Injection site reactions
Warnings
- Boxed warning: thyroid C-cell tumors in rodents
- Contraindicated with personal/family history of medullary thyroid carcinoma
- Risk of pancreatitis
- May worsen diabetic retinopathy
- Not for use with insulin or other GLP-1 agonists
- Gallbladder events reported
Known or Plausible Interactions
- Insulin (increased hypoglycemia risk)
- Sulfonylureas (increased hypoglycemia risk)
- Oral medications (delayed absorption due to slowed gastric emptying)
- Warfarin (monitor INR closely)
Regulatory Context
FDA-approved for type 2 diabetes (Ozempic, 2017), chronic weight management (Wegovy, 2021), cardiovascular risk reduction in adults with established CVD and obesity/overweight, and higher-dose Wegovy HD 7.2mg for weight loss and long-term weight maintenance (March 19, 2026). Prescription required.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss (Level A), Blood Sugar Control (Level A), Cardiovascular Protection (Level A), and GI Side Effects (Level A) |
| Primary citation count | 4 |
| Last reviewed | 2026-06-01 |
Related Guides
How to Cite This Page
ExaminePeptides. "Semaglutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-01. https://examinepeptides.com/answers/semaglutide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.